Craig Hallum Initiates Coverage on PolyPid (NASDAQ:PYPD)

Craig Hallum started coverage on shares of PolyPid (NASDAQ:PYPD) in a research report report published on Monday morning, Benzinga reports. The brokerage issued a buy rating and a $10.00 price objective on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $14.00 target price on shares of PolyPid in a research note on Wednesday, October 2nd.

PolyPid Stock Up 1.2 %

PolyPid stock traded up $0.04 during midday trading on Monday, reaching $3.37. The stock had a trading volume of 310 shares, compared to its average volume of 6,172. The company has a debt-to-equity ratio of 1.95, a quick ratio of 0.95 and a current ratio of 0.95. PolyPid has a 52-week low of $2.95 and a 52-week high of $9.20. The company has a fifty day moving average of $3.48 and a 200 day moving average of $3.87.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($1.25) earnings per share for the quarter, topping the consensus estimate of ($1.51) by $0.26. Equities analysts predict that PolyPid will post -4.39 earnings per share for the current year.

Institutional Trading of PolyPid

An institutional investor recently raised its position in PolyPid stock. Rosalind Advisors Inc. boosted its position in shares of PolyPid Ltd. (NASDAQ:PYPD) by 62.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 679,168 shares of the company’s stock after purchasing an additional 262,368 shares during the quarter. PolyPid comprises about 1.5% of Rosalind Advisors Inc.’s portfolio, making the stock its 18th biggest position. Rosalind Advisors Inc. owned 14.16% of PolyPid worth $2,336,000 at the end of the most recent reporting period. Institutional investors own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.